These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 9783563

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder.
    Fallon BA, Campeas R, Schneier FR, Hollander E, Feerick J, Hatterer J, Goetz D, Davies S, Liebowitz MR.
    J Neuropsychiatry Clin Neurosci; 1992; 4(1):70-5. PubMed ID: 1627966
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ.
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
    Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA.
    J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
    [Abstract] [Full Text] [Related]

  • 10. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.
    Thorén P, Asberg M, Cronholm B, Jörnestedt L, Träskman L.
    Arch Gen Psychiatry; 1980 Nov; 37(11):1281-5. PubMed ID: 7436690
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder.
    Mathew SJ, Coplan JD, Perko KA, Goetz RR, de la Neuz M, Hollander E, Liebowitz MR, Fallon BA.
    Depress Anxiety; 2001 Nov; 14(4):199-208. PubMed ID: 11754126
    [Abstract] [Full Text] [Related]

  • 13. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.
    Karameh WK, Khani M.
    Int J Neuropsychopharmacol; 2015 Jul 28; 19(2):. PubMed ID: 26221004
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
    Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S.
    Psychopharmacology (Berl); 2013 Aug 28; 228(4):633-40. PubMed ID: 23525525
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
    Albert U, Aguglia E, Maina G, Bogetto F.
    J Clin Psychiatry; 2002 Nov 28; 63(11):1004-9. PubMed ID: 12444814
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.